Lipid

Fat is a type of nutrient. You need some fat in your diet but not too much. Fats give you energy and help your body absorb vitamins. Dietary fat also plays a major role in your cholesterol levels.

But not all fats are the same. You should try to avoid:

Saturated fats such as butter, solid shortening, and lard
Trans fats. These are found in vegetable shortenings, some margarines, crackers, cookies, snack foods, and other foods made with or fried in partially hydrogenated oils (PHOs). By 2018, most U.S. companies will not be allowed to add PHOs to food.

Try to replace them with oils such as canola, olive, safflower, sesame, or sunflower. Of course, eating too much fat will put on the pounds. Fat has twice as many calories as proteins or carbohydrates.

NIH: National Heart, Lung, and Blood Institute

Lipid FDA Approved Drugs

ANTARA (MICRONIZED) [Fenofibrate^{C₂₀H₂₁ClO₄}]

130mg (oral capsule)

43mg (oral capsule)

90mg (oral capsule)

Lupin Atlantis^{Nov 30, 2004}

Treating hypercholesterolemias with reduction of food effect.
Treating hypertriglyceridemias with reduction of food effect.
Treating primary hypercholesterolemia and mixed dyslipidemia.
Treating severe hypertriglyceridemia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CADUET [Amlodipine Besylate^{C₂₀H₂₅ClN₂O₅C₆H₆O₃S} : Atorvastatin Calcium]

eq 10mg base : eq 10mg base (oral tablet)

eq 10mg base : eq 20mg base (oral tablet)

eq 10mg base : eq 40mg base (oral tablet)

eq 10mg base : eq 80mg base (oral tablet)

eq 2.5mg base : eq 10mg base (oral tablet)

eq 2.5mg base : eq 20mg base (oral tablet)

eq 2.5mg base : eq 40mg base (oral tablet)

eq 5mg base : eq 10mg base (oral tablet)

eq 5mg base : eq 20mg base (oral tablet)

eq 5mg base : eq 40mg base (oral tablet)

eq 5mg base : eq 80mg base (oral tablet)

Pfizer^{Jan 30, 2004}

Treatment of hypertension and hyperlipidemia with a single composition.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CLINOLIPID 20% [Olive Oil : Soybean Oil]

16%(160gm/1000ml) : 4% (40gm/1000ml) (injection injectable)

Baxter Hlthcare Corp^{Oct 3, 2013}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CRESTOR [Rosuvastatin Calcium^{2C₂₂H₂₇FN₃O₆SCa}]

10mg (oral tablet)

20mg (oral tablet)

40mg (oral tablet)

5mg (oral tablet)

Ipr^{Aug 12, 2003}

Treatment of pediatric patients 8 to 17 years of age with heterozygous familial hypercholesterolemia (hefh).
Use of rosuvastatin calcium for the primary prevention of cardiovascular disease in individuals without clinically evident coronary heart disease but with increased risk factors.
Use of rosuvastatin calcium to reduce elevated total-c, ldl-c, apob, nonhdl-c or tg levels; to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia; and to slow the progression of atherosclerosis..

efficacy
4.5 (2)

side effects
1.0 (1)

danger
1.0 (1)

FENOFIBRATE [Fenofibrate^{C₂₀H₂₁ClO₄}]

107mg (oral tablet)

120mg (oral tablet)

130mg (oral capsule)

145mg (oral tablet)

160mg (oral tablet)

40mg (oral tablet)

43mg (oral capsule)

48mg (oral tablet)

54mg (oral tablet)

Sun Pharm Inds Ltd^{Oct 31, 2005}
Mylan^{Jun 23, 2016}
Aurobindo Pharma Ltd^{May 5, 2016}
Cipla Ltd^{Dec 15, 2016}
Hetero Labs Ltd Iii^{Jul 12, 2016}
Lupin Ltd^{Dec 23, 2011}
Mylan Pharms Inc^{Dec 7, 2012}
Valeant Pharms North^{Apr 5, 2012}
Impax Labs^{Mar 26, 2008}
Rhodes Pharms^{May 13, 2005}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

FENOFIBRATE (MICRONIZED) [Fenofibrate^{C₂₀H₂₁ClO₄}]

130mg (oral capsule)

134mg (oral capsule)

200mg (oral capsule)

43mg (oral capsule)

67mg (oral capsule)

Apotex Inc^{Jul 26, 2013}
Dr Reddys Labs Sa^{Mar 1, 2012}
Mylan Pharms Inc^{Jan 10, 2013}
Glenmark Pharms Ltd^{Apr 7, 2017}
Impax Labs^{Oct 27, 2003}
Invagen Pharms^{Mar 28, 2017}
Rhodes Pharms^{Apr 9, 2002}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

FENOGLIDE [Fenofibrate^{C₂₀H₂₁ClO₄}]

120mg (oral tablet)

40mg (oral tablet)

Santarus Inc^{Aug 10, 2007}

For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia.
Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

FIBRICOR [Fenofibric Acid^{C₁₇H₁₅ClO₄}]

105mg (oral tablet)

35mg (oral tablet)

Aralez Pharms Inc^{Aug 14, 2009}

Adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels.
Adjunctive therapy to diet in patients with hyperlipidemias.
Adjunctive therapy to diet in patients with mixed dyslipidemia.
Adjunctive therapy to diet to patients with hypertriglyceridemia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

INTRALIPID 10% [Soybean Oil]

10% (injection injectable)

Fresenius^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

INTRALIPID 20% [Soybean Oil]

20% (injection injectable)

Fresenius^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

INTRALIPID 30% [Soybean Oil]

30% (injection injectable)

Fresenius^{Dec 30, 1993}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

JUXTAPID [Lomitapide Mesylate^{C₃₉H₃₇F₆N₃O₂CH₄O₃S}]

eq 10mg base (oral capsule)

eq 20mg base (oral capsule)

eq 30mg base (oral capsule)

eq 40mg base (oral capsule)

eq 5mg base (oral capsule)

eq 60mg base (oral capsule)

Aegerion^{Dec 21, 2012}

A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses.
A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses.
Treatment of hypercholesterolemia by decreasing the amount or activity of microsomal triglyceride transfer protein in patients with homozygous familial hypercholesterolemia.
Treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

KYNAMRO [Mipomersen Sodium^{C₂₃₀H₃₀₅N₆₇O₁₂₂P₁₉S₁₉1₉Na}]

200mg/ml (200mg/ml) (subcutaneous solution)

Kastle Theraps Llc^{Jan 29, 2013}

Adjunctive therapy to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein b, total cholesterol, and non-high density lipoprotein cholesterol in pts with homozygous familial hypercholesterolemia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIPOFEN [Fenofibrate^{C₂₀H₂₁ClO₄}]

150mg (oral capsule)

Cipher Pharms Inc^{Jan 11, 2006}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LIVALO [Pitavastatin Calcium^{2C₂₅H₂₃FNO₄Ca}]

eq 1mg base (oral tablet)

eq 2mg base (oral tablet)

eq 4mg base (oral tablet)

Kowa Co^{Aug 3, 2009}

Adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprtein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LUMASON [Sulfur Hexafluoride Lipid-type A Microspheres]

60.7mg/25mg (intravenous for suspension)

Bracco^{Oct 15, 2014}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

NIASPAN [Niacin^{C₆H₅NO₂}]

1gm (oral tablet, extended release)

500mg (oral tablet, extended release)

750mg (oral tablet, extended release)

Abbvie^{Jul 28, 1997}

A method of reducing the capacity of extended release nicotinic acid to provoke a flushing reaction by pretreating an individual with a flush inhibiting agent prior to the administration of the extended release nicotinic acid.
Method of treating hyperlipidemia with nicotinic acid by dosing once per day in the evening or at night.
Reduction in elevated tc and ldl-c by dosing once per day in the evening or at night, with pretreatment with a flush inhibitin agent such as aspirin.
Reduction in elevated tc and ldl-c by dosing once per day in the evening or at night.
Reduction in risk of recurrent nonfatal myocardial infarction by dosing once per day in the evening or a t night, with pretreatment with a flush inhibitin agent such as aspirin.
Reduction in risk of recurrent nonfatal myocardial infarction by dosing once per day in the evening or at night.
Reduction in tg by dosing once per day in the evening or at night, with pretreatment with a flush inhibiting agent such as aspirin.
Reduction in tg by dosing once per day in the evening or at night.
Treatment of primary and mixed dyslipidemia by dosing once per day in the evening or at night, with pretreatment with a flush inhibiting agent such as aspirin.
Treatment of primary and mixed dyslipidemia by dosing once per day in the evening or at night.

efficacy
3.0 (1)

side effects
0.0 (0)

NUTRILIPID 10% [Soybean Oil]

10% (injection injectable)

B Braun^{May 28, 1993}

NUTRILIPID 20% [Soybean Oil]

20% (injection injectable)

B Braun^{May 28, 1993}

SMOFLIPID 20% [Fish Oil : Medium Chain Triglycerides : Olive Oil : Soybean Oil]

3gm/100ml : 6gm/100ml : 5gm/100ml : 6gm/100ml (100ml) (intravenous emulsion)

3gm/100ml : 6gm/100ml : 5gm/100ml : 6gm/100ml (250ml) (intravenous emulsion)

3gm/100ml : 6gm/100ml : 5gm/100ml : 6gm/100ml (500ml) (intravenous emulsion)

Fresenius Kabi Usa^{Jul 13, 2016}

TRICOR [Fenofibrate^{C₂₀H₂₁ClO₄}]

145mg (oral tablet)

48mg (oral tablet)

Abbvie^{Nov 5, 2004}

Adjunctive therapy to diet in adults to reduce ldl-c, total-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v).
Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v).

TRIGLIDE [Fenofibrate^{C₂₀H₂₁ClO₄}]

160mg (oral tablet)

Skyepharma Ag^{May 7, 2005}

A method of treating dyslipidemia and dyslipoproteinemia using a dosage form that can provide an effective amount of fenofibrate to a patient in a fasted state which is at least 90% of the auc amount provided by the dosage form.

ZETIA [Ezetimibe^{C₂₄H₂₁F₂NO₃}]

10mg (oral tablet)

Msd Intl Gmbh^{Oct 25, 2002}

Reduction of elevated plasma sterol and/or stanol levels in a mammal.
To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate.
To reduce plasma cholesterol levels in a mammal.

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Lipid

Lipid FDA Approved Drugs